Novel selective melanocortin 4 receptor antagonist induces food intake after peripheral administration

Biochemical and Biophysical Research Communications

Volumn 301, Issue 2, 2003, Pages 399-405

  Schiöth, Helgi B ^a   Kask, Ants ^b   Mutulis, Felikss ^c   Muceniece, Ruta ^c   Mutule, Ilga ^a   Mutule, Ilze ^a   Mandrika, Ilona ^a   Wikberg, Jarl E S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

^c LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

Author keywords

Food intake; HS131; Melanocortin 4 receptor; MSH

Indexed keywords

ALPHA INTERMEDIN; BETA INTERMEDIN[11-22][11 (N ACETYLCYSTEINE) 14 (3,4 DICHLORO DEXTRO PHENYLALANINE) 18 CYSTEINE 22 ASPARTIC ACID AMIDE] 11,18 CYCLIC DISULFIDE; HS 131; HS 132; HS 134; HS 135; HS 136; HS 137; HS 139; HS 140; HS 141; HS 142; INTERMEDIN DERIVATIVE; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; PEPTIDE HORMONE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; FOOD INTAKE; HUMAN; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0037423757     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)03065-6     Document Type: Article

References (28)

1. Gantz I., Miwa H., Konda Y., Shimoto Y., Tashiro T., Watson S.J., Del Valle J., Yamada T. J. Biol. Chem. 268:1993;15174-15179.
2. Mountjoy K.G., Mortrud M.T., Low M.J., Simerly R.B., Cone R.D. Mol. Endocrinol. 8:1994;1298-1308.
3. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., Smith F.J., Campfield L.A., Burn P., Lee F. Cell. 88:1997;131-141.
4. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., Cone R.D. Nature. 385:1997;165-168.
5. Kask A., Rägo L., Mutulis F., Pähkla R., Wikberg J.E.S., Schiöth H.B. Biochem. Biophys. Res. Commun. 245:1998;90-93.
6. L.H. Van derPloeg, W.J. Martin, A.D. Howard, R.P. Nargund, C.P. Austin, X. Guan, J. Drisko, D. Cashen, I. Sebhat, A.A. Patchett, D.J. Figueroa, A.G. DiLella, B.M. Connolly, D.H. Weinberg, C.P Tan, O.C. Palyha, S.S. Pong, T. MacNeil, C. Rosenblum, A. Vongs, R. Tang, H. Yu, A.W. Sailer, T.M. Fong, C. Huang, M.R. Tota, R.S. Chang, R. Stearns, R. Tamvakopoulos, G. Christ, D.L. Drazen, B.D. Spar, R.J. Nelson, D.E. MacIntyre, Proc. Natl. Acad. Sci. USA. 99, 11381-11386.
7. Schiöth H.B. Vitam. Horm. 63:2001;195-232.
8. Schiöth H.B., Watanobe H. Brain Res. Brain Res. Rev. 38:2000;340-350.
9. A.S. Chen, D.J. Marsh, M.E. Trumbauer, E.G. Frazier, X.M. Guan, H. Yu, C.I. Rosenblum.
10. Vongs A., Feng Y., Cao L., Metzger J.M., Strack A.M., Camacho R.E., Mellin T.N., Nunes C.N., Min W., Fisher J., Gopal-Truter S., MacIntyre D.E., Chen H.Y., Van der Ploeg L.H. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26:2000;97-102.
11. Chen W., Kelly M.A., Opitz-Araya X., Thomas R.E., Low M.J., Cone R.D. Cell. 91:1997;789-798.
12. Al-Obeidi F., Castrucci A.L., Hadley M.E., Hruby V.J. Potent and prolonged acting cyclic lactam analogues of a-melanotropin: design based on molecular dynamics. J. Med. Chem. 32:1989;2555-2561.
13. Hruby V.J., Lu D., Sharma S.D., Castrucci A.L., Kesterson R.A., Al-Obeidi F.A., Hadley M.E., Cone R.D. J. Med. Chem. 38:1995;3454-3461.
14. Schiöth H.B., Mutulis F., Muceniece R., Prusis P., Wikberg J.E.S. Br. J. Pharmacol. 124:1998;75-82.
15. Skuladottir G.V., Jonsson L., Skarphedinsson J.O., Mutulis F., Muceniece R., Raine A., Mutule I., Helgason J., Prusis P., Wikberg J.E.S., Schiöth H.B. Br. J. Pharmacol. 126:1999;27-34.
16. Kask A., Mutulis F., Muceniece R., Pähkla R., Mutule I., Wikberg J.E.S., Rägo L., Schiöth H.B. Endocrinology. 139:1998;5006-5014.
17. Wessells H., Fuciarelli K., Hansen J., Hadley M.E., Hruby V.J., Dorr R., Levine N. J. Urol. 160:1998;389-393.
18. Schiöth H.B., Muceniece R., Wikberg J.E.S. Pharmacol. Toxicol. 79:1996;161-165.
19. Schiöth H.B., Muceniece R., Wikberg J.E.S., Chhajlani V. Eur. J. Pharmacol. 288:1995;311-317.
20. Nordstedt C., Fredholm B.B. Anal. Chem. 189:1990;231-234.
21. Schiöth H.B., Muceniece R., Mutulis F., Prusis P., Lindeberg G., Sharma S.D., Hruby V.J., Wikberg J.E.S. Peptides. 18:1997;1009-1013.
22. Jonsson L., Skarphedinsson J.O., Skuladottir G.V., Watanobe H., Schiöth H.B. J. Endocrinol. 173:2002;517-523.
23. Kask A., Pahkla R., Irs A., Rago L., Wikberg J.E., Schiöth H.B. Neuroreport. 10:2002;707-711.
24. Marks D.L., Ling N., Cone R.D. Cancer Res. 61:2001;1432-1438.
25. Vergoni A.V., Bertolini A., Wikberg J.E., Schiöth H.B. Eur. J. Pharmacol. 369:1999;11-15.
26. Vink T., Hinney A., van Elburg A.A., van Goozen S.H., Sandkuijl L.A., Sinke R.J., Herpertz-Dahlmann B.M., Hebebrand J., Remschmidt H., van Engeland H., Adan R.A. Mol. Psychiatr. 6:2000;325-328.
27. Morley J.E. Nutrition. 17:2001;660-663.
28. Carel J.C., Chaussain J.L. Horm. Res. 51:1999;64-69.